Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1569-1585

  Benhnia, Mohammed Rafii El Idrissi ^a,g   Maybeno, Matthew ^a   Blum, David ^b   Aguilar Sino, Rowena ^c   Matho, Michael ^a   Meng, Xiangzhi ^f   Head, Steven ^c   Felgner, Philip L ^d   Zajonc, Dirk M ^a   Koriazova, Lilia ^e   Kato, Shinichiro ^e   Burton, Dennis R ^c   Xiang, Yan ^f   Crowe, James E ^b   Peters, Bjoern ^a   Crotty, Shane ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MEMBRANE PROTEIN A34; MONOCLONAL ANTIBODY; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VACCINIA ANTIGEN A33; VACCINIA ANTIGEN A56; VACCINIA ANTIGEN B5; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CELL INTERACTION; COMPLEMENT SYSTEM; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; TARGET CELL; VACCINIA VIRUS; VIRION; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; NEUTRALIZATION TESTS; SMALLPOX VACCINE; VACCINIA VIRUS; VIRION;

EID: 84873026488     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02152-12     Document Type: Article

References (110)

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
2. Reference deleted.
3. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K. 1999. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:2127-2137.
4. LeDuc JW, Jahrling PB. 2001. Strengthening national preparedness for smallpox: an update. Emerg. Infect. Dis. 7:155-157.
5. Meltzer MI, Damon I, LeDuc JW, Millar JD. 2001. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7:959-969.
6. NIAID. 2007. NIAID high priority biodefense products. NIAID, Bethesda, MD.
7. O'Toole T, Mair M, Inglesby TV. 2002. Shining light on "Dark Winter." Clin. Infect. Dis. 34:972-983.
8. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, Damon IK, Reynolds MG, Kuehnert MJ. 2005. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis. 41:1742-1751.
9. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, Damon IK. 2006. Clinical manifestations of human monkeypox influenced by route of infection. J. Infect. Dis. 194:773-780.
10. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11: 740-747.
11. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, Wong SW, Yoshihara P, Hanifin JM, Slifka MK. 2005. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 11:1005-1011.
12. Karem K, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, Glidewell J, Ahmed R, Amara R, Damon I. 2007. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin. Vaccine Immunol. 14:1318-1327.
13. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, Davidson W, Galloway R, Khristova ML, Reynolds MG, Zhao H, Carroll DS, Curns A, Formenty P, Esposito JJ, Regnery RL, Damon I. 2005. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86:2661-2672.
14. Condit RC, Moussatche N, Traktman P. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66:31-124.
15. Laliberte JP, Moss B. 2010. Lipid membranes in poxvirus replication. Viruses 2:972-986.
16. Roberts KL, Smith GL. 2008. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16:472-479.
17. Smith GL, Vanderplasschen A, Law M. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
18. Laliberte JP, Weisberg AS, Moss B. 2011. The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components. PLoS Pathog. 7:e1002446.
19. Moss B. 2007. Poxviridae: the viruses and their replication. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams&Wilkins, Philadelphia, PA.
20. Moss B. 2011. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239:8-26.
21. Doceul V, Hollinshead M, Breiman A, Laval K, Smith GL. 2012. Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of super-infecting virions. J. Gen. Virol. 93(Pt 9):1876-1886.
22. Doceul V, Hollinshead M, van der Linden L, Smith GL. 2010. Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327:873-876.
23. Smith GL, Murphy BJ, Law M. 2003. Vaccinia virus motility. Annu. Rev. Microbiol. 57:323-342.
24. Payne LG. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50:89-100.
25. Roper RL, Payne LG, Moss B. 1996. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J. Virol. 70:3753-3762.
26. Duncan SA, Smith GL. 1992. Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress. J. Virol. 66:1610-1621.
27. Parkinson JE, Smith GL. 1994. Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. Virology 204:376-390.
28. Shida H. 1986. Nucleotide sequence of the vaccinia virus hemagglutinin gene. Virology 150:451-462.
29. Isaacs SN, Wolffe EJ, Payne LG, Moss B. 1992. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:7217-7224.
30. Sanderson CM, Frischknecht F, Way M, Hollinshead M, Smith GL. 1998. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J. Gen. Virol. 79(Pt 6):1415-1425.
31. Wolffe EJ, Weisberg AS, Moss B. 1998. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. Virology 244:20-26.
32. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
33. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
34. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, Da Rosa AP, Tesh RB. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
35. Chung CS, Huang CY, Chang W. 2005. Vaccinia virus penetration requires cholesterol and results in specific viral envelope proteins associated with lipid rafts. J. Virol. 79:1623-1634.
36. Laliberte JP, Moss B. 2009. Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proc. Natl. Acad. Sci. U. S. A. 106:17517-17521.
37. Mercer J, Helenius A. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320:531-535.
38. Mercer J, Knebel S, Schmidt FI, Crouse J, Burkard C, Helenius A. 2010. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc. Natl. Acad. Sci. U. S. A. 107:9346-9351.
39. Oie M. 1985. Reversible inactivation and reactivation of vaccinia virus by manipulation of viral lipid composition. Virology 142:299-306.
40. Morizono K, Xie Y, Olafsen T, Lee B, Dasgupta A, Wu AM, Chen IS. 2011. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9:286-298.
41. Walker BD, Burton DR. 2008. Toward an AIDS vaccine. Science 320: 760-764.
42. Amanna IJ, Slifka MK, Crotty S. 2006. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211:320-337.
43. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325:425-431.
44. Benhnia MR, McCausland MM, Su HP, Singh K, Hoffmann J, Davies DH, Felgner PL, Head S, Sette A, Garboczi DN, Crotty S. 2008. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 82:3751-3768.
45. Kempe CH, Bowles C, Meiklejohn G, Berge TO, St Vincent L, Babu BV, Govindarajan S, Ratnakannan NR, Downie AW, Murthy VR. 1961. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull. World Health Organ. 25:41-48.
46. Mack TM, Noble J, Jr, Thomas DB. 1972. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21: 214-218.
47. Moyron-Quiroz JE, McCausland MM, Kageyama R, Sette A, Crotty S. 2009. The smallpox vaccine induces an early neutralizing IgM response. Vaccine 28:140-147.
48. Benhnia MR, McCausland MM, Laudenslager J, Granger SW, Rickert S, Koriazova L, Tahara T, Kubo RT, Kato S, Crotty S. 2009. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J. Virol. 83:12355-12367.
49. Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S. 2009. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83:1201-1215.
50. Chen Z, Earl P, Americo J, Damon I, Smith SK, Yu F, Sebrell A, Emerson S, Cohen G, Eisenberg RJ, Gorshkova I, Schuck P, Satterfield W, Moss B, Purcell R. 2007. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J. Virol. 81:8989-8995.
51. McCausland MM, Benhnia MR, Crickard L, Laudenslager J, Granger SW, Tahara T, Kubo R, Koriazova L, Kato S, Crotty S. 2010. Combination therapy of vaccinia virus infection with human anti-H3 and anti- B5 monoclonal antibodies in a small animal model. Antivir. Ther. 15:661-675.
52. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. U. S. A. 102:547-552.
53. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, Monath TP. 2008. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26:581-588.
54. Davies DH, Molina D, Wrammert J, Miller J, Hirst S, Mu Y, Pablo J, Unal B, Nakajima-Sasaki R, Liang X, Crotty S, Karem K, Damon I, Ahmed R, Villarreal L, Felgner P. 2007. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7:1678-1686.
55. Johnson BF, Kanatani Y, Fujii T, Saito T, Yokote H, Smith GL. 2011. Serological responses in humans to the smallpox vaccine LC16m8. J. Gen. Virol. 92:2405-2410.
56. Lawrence SJ, Lottenbach KR, Newman FK, Buller RM, Bellone CJ, Chen JJ, Cohen GH, Eisenberg RJ, Belshe RB, Stanley SL, Jr, Frey SE. 2007. Antibody responses to vaccinia membrane proteins after smallpox vaccination. J. Infect. Dis. 196:220-229.
57. Pütz MM, Midgley CM, Law M, Smith GL. 2006. Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12:1310-1315.
58. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71-80.
59. Lustig S, Fogg C, Whitbeck JC, Moss B. 2004. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328:30-35.
60. Parren PW, Burton DR. 2001. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77:195-262.
61. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111.
62. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
63. Klasse PJ. 2007. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369:245-262.
64. Klasse PJ, Burton D. 2007. Antibodies to West Nile virus: a doubleedged sword. Cell Host Microbe 1:87-89.
65. Li L, Coelingh KL, Britt WJ. 1995. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J. Virol. 69:6047-6053.
66. Pierson T, Xu Q, Nelson S, Oliphant T, Nybakken G, Fremont D, Diamond M. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145.
67. Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN. 2011. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One 6:e20597.
68. Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina D, Hirst S, Moss B, Frey SE, Felgner PL. 2008. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J. Virol. 82:652-663.
69. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. 2005. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79:13454-13462.
70. Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Hirao L, Isaacs SN, Moss B, Eisenberg RJ, Cohen GH. 2005. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J. Virol. 79:6260-6271.
71. Su HP, Singh K, Gittis AG, Garboczi DN. 2010. The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains. J. Virol. 84:2502-2510.
72. Yu X, McGraw PA, House FS, Crowe JE, Jr. 2008. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. J. Immunol. Methods 336:142-151.
73. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
74. Meng X, Zhong Y, Embry A, Yan B, Lu S, Zhong G, Xiang Y. 2011. Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus. Virology 409:271-279.
75. Tiller T, Busse CE, Wardemann H. 2009. Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350:183-193.
76. Brochet X, Lefranc MP, Giudicelli V. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG andTRstandardized V-J. and V-D-J. sequence analysis. Nucleic Acids Res. 36:W503-W508.
77. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4:372-384.
78. Vanderplasschen A, Hollinshead M, Smith GL. 1997. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78(Pt 8):2041-2048.
79. Law M, Hollinshead R, Smith GL. 2002. Antibody-sensitive and antibody- resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J. Gen. Virol. 83:209-222.
80. Law M, Smith GL. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132-142.
81. Cyrklaff M, Risco C, Fernandez JJ, Jimenez MV, Esteban M, Baumeister W, Carrascosa JL. 2005. Cryo-electron tomography of vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 102:2772-2777.
82. Gaylord WH, Jr, Melnick JL. 1953. Intracellular forms of pox viruses as shown by the electron microscope (Vaccinia, Ectromelia, Molluscum Contagiosum). J. Exp. Med. 98:157-172.
83. Morgan C, Ellison SA, Rose HM, Moore DH. 1954. Internal structure in virus particles. Nature 173:208.
84. Morgan C, Ellison SA, Rose HM, Moore DH. 1954. Structure and development of viruses observed in the electron microscope. II. Vaccinia and fowl pox viruses. J. Exp. Med. 100:301-310.
85. Chung CS, Chen CH, Ho MY, Huang CY, Liao CL, Chang W. 2006. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J. Virol. 80:2127-2140.
86. Hulander M, Lundgren A, Berglin M, Ohrlander M, Lausmaa J, Elwing H. 2011. Immune complement activation is attenuated by surface nanotopography. Int. J. Nanomed. 6:2653-2666.
87. Resch W, Hixson KK, Moore RJ, Lipton MS, Moss B. 2007. Protein composition of the vaccinia virus mature virion. Virology 358:233-247.
88. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78:10230-10237.
89. DeHaven BC, Girgis NM, Xiao Y, Hudson PN, Olson VA, Damon IK, Isaacs SN. 2010. Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J. Virol. 84:11245-11254.
90. Girgis NM, Dehaven BC, Fan X, Viner KM, Shamim M, Isaacs SN. 2008. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J. Virol. 82:4205-4214.
91. Isaacs SN, Argyropoulos E, Sfyroera G, Mohammad S, Lambris JD. 2003. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J. Virol. 77:8256-8262.
92. Isaacs SN, Kotwal GJ, Moss B. 1992. Vaccinia virus complementcontrol protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U. S. A. 89:628-632.
93. McIntosh AA, Smith GL. 1996. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol. 70:272-281.
94. Bachmann MF, Zinkernagel RM. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:235-270.
95. Burton D. 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2:706-713.
96. Karlsson Hedestam G, Fouchier RA, Phogat S, Burton D, Sodroski J, Wyatt R. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6:143-155.
97. Schmidt FI, Bleck CK, Helenius A, Mercer J. 2011. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 30:3647-3661.
98. Feng JQ, Mozdzanowska K, Gerhard W. 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutinin- specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J. Virol. 76:1369-1378.
99. Johnson JB, Capraro GA, Parks GD. 2008. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376:112-123.
100. Leddy JP, Simons RL, Douglas RG. 1977. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera. J. Immunol. 118:28-34.
101. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, Pierson TC, Diamond MS. 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass- specific manner. Cell Host Microbe 2:417-426.
102. Mehlhop E, Diamond MS. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
103. Mehlhop E, Fuchs A, Engle M, Diamond MS. 2009. Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology 393:11-15.
104. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-391.
105. Moulton EA, Atkinson JP, Buller RM. 2008. Surviving mousepox infection requires the complement system. PLoS Pathog. 4:e1000249.
106. Berry DM, Almeida JD. 1968. The morphological and biological effects of various antisera on avian infectious bronchitis virus. J. Gen. Virol. 3:97-102.
107. Friedman HM, Wang L, Pangburn MK, Lambris JD, Lubinski J. 2000. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J. Immunol. 165:4528-4536.
108. Radwan AI, Burger D. 1973. The complement-requiring neutralization of equine arteritis virus by late antisera. Virology 51:71-77.
109. Stollar V. 1975. Immune lysis of Sindbis virus. Virology 66:620-624.
110. Welsh RM, Jr, Lampert PW, Burner PA, Oldstone MB. 1976. Antibody- complement interactions with purified lymphocytic choriomeningitis virus. Virology 73:59-71.